Multicenter Evaluation of the Biochip Assay for Rapid Detection of Mycobacterial Isolates in Smear-Positive Specimens
Hong Fang,Yanwan Shangguan,Hao Wang,Zhongkang Ji,Jundan Shao,Ruihong Zhao,Shuting Wang,Lin Zheng,Xiuyuan Jin,Shujuan Huang,Kaijin Xu,Jifang Sheng
DOI: https://doi.org/10.1016/j.ijid.2019.01.036
IF: 12.073
2019-01-01
International Journal of Infectious Diseases
Abstract:Objectives: The objective of this study was to conduct a multicentre evaluation of the performance of the biochip assay in the rapid identification of mycobacteria in smear-positive sputum specimens. Methods: A total of 1751 sputum specimens were obtained from 7 cities in Zhejiang, China. All of the specimens were used for the discrimination of Mycobacterium species using the biochip assay, and the results were compared to the golden standard method of culture, hsp65, 16S rRNA and rpoB sequence analysis. Results: In the 1751 sputum specimens, 1685 samples were cultured successfully; among these samples, 1361 were Mycobacterium tuberculosis, 323 were NTM and 1 was Nocadia farcinica. Of the 323 NTM, most of them were Mycobacterium intracellulare(52.5%) followed by Mycobacterium abscessus (20.7%), Mycobacterium avium (11.7%), Mycobacterium kansasii (9.6%) and Mycobacterium fortuitum (1.9%). The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the biochip assay to differentiate TB and NTM from AFB positive specimens were 99.8%, 99.7%, 99.9%, 99.1%, 98.8%, 1,1, and 99.7%, respectively. The concordance between the biochip assay and mycobacterial culture for the identification of NTM species was 95.4%. Conclusions: The biochip assay is a reliable tool for the rapid identification of most mycobacteria in clinical sputum specimens. This assay can be helpful for physicians in the early diagnosis and treatment of mycobacterium infections. (C) 2019 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.